Showing results (151-160 of 159) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 159 results.
Infection and Immunity|August 19, 2000
Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibodyA M Cevallos, N Bhat, R Verdon, et al.
The American Journal of Clinical Nutrition|March 13, 1999
Relative influences of sex, race, environment, and HIV infection on body composition in adultsD P Kotler, D M Thea, M Heo, et al.
The New England Journal of Medicine|October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.
Journal of Leukocyte Biology|December 1, 1992
Interleukin-1 beta (IL-1 beta), IL-1 receptor antagonist, and TNF alpha production in whole bloodJ L Nerad, J K Griffiths, J W Van der Meer, et al.
Gastroenterology|September 29, 1999
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseP Rutgeerts, G D'Haens, S Targan, et al.
Alimentary Pharmacology & Therapeutics|October 20, 2010
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapyS Lichtiger, D G Binion, D C Wolf, et al.
The New England Journal of Medicine|May 6, 1999
Infliximab for the treatment of fistulas in patients with Crohn's diseaseD H Present, P Rutgeerts, S Targan, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Pageof 16